Enviva Partners Logo
US29414J1079

Enviva Partners

Ins Portfolio
80% Chancen, 20% Gelassenheit: Aktien und Anleihen in einem LifeStrategy-ETF.Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +54,90(+14.837.737,84%). Der Median liegt bei +60,47(+16.343.143,24%).

Kaufen
  6
Halten
  3
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie3 / 18
Levermann-Strategie-6 / 13
Powered byaktien.guide

News

  • Foto von Taiwan's EVA Air activates NDC connection with Sabre

    Taiwan's EVA Air activates NDC connection with Sabre

    The addition of EVA Air advances Sabre's multi-source content strategy by expanding booking options for travel agencies SOUTHLAKE, Texas and SINGAPORE and TAIPEI CITY, Taiwan , Nov. 21, 2024 /PRNewswire/ --  Sabre Corporation  (NASDAQ: SABR), a leading software and technology provider that powers the global travel industry, today announced New Distribution Capability (NDC) connectivity from Star Alliance member and five-star SKYTRAX airline, EVA Air, through Sabre's global multi-source content platform. With this new connection, EVA Air's NDC content will be seamlessly integrated into Sabre's global distribution system (GDS), allowing travel agencies and corporate buyers to compare flight options with greater efficiency and transparency.» Mehr auf prnewswire.com

  • Foto von Eli Lilly to license arthritis drug to Egypt's EVA Pharma

    Eli Lilly to license arthritis drug to Egypt's EVA Pharma

    Eli Lilly and Egypt's EVA Pharma have entered into an agreement to license Lilly's rheumatoid arthritis drug in 49 countries in Africa, the companies said on Wednesday.» Mehr auf reuters.com

  • Foto von Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

    Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

    Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa INDIANAPOLIS and CAIRO , Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and  EVA Pharma  announced today that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030.» Mehr auf prnewswire.com

Dividenden

Alle Kennzahlen
In 2022 hat Enviva Partners +0,84 Dividende ausgeschüttet. Die letzte Dividende wurde im Mai 2022 gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Enviva Partners einen Umsatz von +282,87 Mio und ein Nettoeinkommen von 387,22 Mio
(EUR)Dez. 2023
YOY
Umsatz+282,87 Mio-
Bruttoeinkommen243,59 Mio-
Nettoeinkommen387,22 Mio-
EBITDA288,38 Mio-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+30,02 Mio
Anzahl Aktien
74,50 Mio
52 Wochen-Hoch/Tief
+6,50 - +0,24
DividendenNein
Beta
0,84
KGV (PE Ratio)
0,05
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,26
KUV (PS Ratio)
+0,03

Unternehmensprofil

Name
Enviva Partners
CEO
Glenn T. Nunziata
SitzBethesda, md
USA
Mitarbeiter1.234

Ticker Symbole

BörseSymbol
NYSE
EVA

Assets entdecken

Shareholder von Enviva Partners investieren auch in folgende Assets

🍪

Parqetnutzt Cookies.Erfahre Mehr